Merck KGaA, Darmstadt, Germany has announced one of the largest biotechnology acquisitions of 2026 by agreeing to acquire Bio-Techne Corporation in an all-cash transaction valued at approximately $11.3 billion.
Under the agreement, Bio-Techne shareholders will receive $73 per share in cash, representing a significant premium over the company’s recent average trading price. The acquisition has been unanimously approved by the boards of both companies and is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals.
The deal is designed to strengthen Merck’s position in high-growth areas such as multiomics, proteomics, spatial biology, cell and gene therapy, precision medicine, and advanced life science research.
Deal Overview
| Item | Details |
| Acquirer | Merck KGaA, Darmstadt, Germany |
| Target Company | Bio-Techne Corporation |
| Deal Value | $11.3 Billion |
| Offer Price | $73 per share (Cash) |
| Transaction Type | All-Cash Acquisition |
| Expected Closing | Late 2026 / Early 2027 |
| Industry | Life Science & Biotechnology |
More Deal : Click here
About Merck KGaA
Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA is one of the world’s oldest science and technology companies.
The company operates through three major business segments:
- Life Science
- Healthcare
- Electronics
Its Life Science division supplies laboratory chemicals, filtration technologies, cell culture products, research tools, analytical instruments, and bioprocessing solutions to pharmaceutical companies, biotechnology firms, universities, and research laboratories worldwide.
Today, Merck serves customers in more than 60 countries and is recognized as one of the global leaders in life science solutions.
About Bio-Techne
Bio-Techne Corporation is a leading U.S.-based biotechnology company headquartered in Minneapolis, Minnesota.
The company develops advanced life science tools used in scientific research, drug discovery, diagnostics, and biopharmaceutical manufacturing.
Its product portfolio includes:
- Proteins
- Antibodies
- Research Reagents
- Diagnostic Solutions
- Analytical Instruments
- Multiomics Technologies
- Spatial Biology Platforms
Bio-Techne’s products are widely used by pharmaceutical companies, biotechnology firms, hospitals, universities, and research organizations around the world.
Why Is Merck Acquiring Bio-Techne?
The biotechnology industry is undergoing a major transformation.
Modern drug development increasingly depends on technologies such as:
- Artificial Intelligence (AI)
- Multiomics
- Genomics
- Proteomics
- Spatial Biology
- Cell Therapy
- Gene Therapy
Merck already has a strong global Life Science business. However, Bio-Techne adds cutting-edge research technologies that complement Merck’s existing strengths.
By combining both companies, Merck aims to become an even stronger partner for scientists—from early-stage research to commercial-scale biopharmaceutical manufacturing.
How Will Both Companies Complement Each Other?
Merck’s Strengths
- Global manufacturing capabilities
- Worldwide distribution network
- Strong pharmaceutical customer relationships
- Large-scale production infrastructure
Bio-Techne’s Strengths
- Advanced research tools
- Proteomics technologies
- Multiomics platforms
- Spatial biology solutions
- Analytical instruments
- Scientific innovation
Together, they will offer customers a more comprehensive portfolio covering every stage of scientific research, drug development, testing, and commercial manufacturing.
Key Growth Areas
1. Drug Discovery
Researchers will gain access to broader scientific tools that can help accelerate the discovery of new medicines.
2. Cell & Gene Therapy
The combined business will strengthen Merck’s presence in one of the fastest-growing areas of biotechnology.
3. Precision Medicine
The acquisition will support the development of personalized treatments by combining advanced biological data with innovative research technologies.
4. Diagnostics
Bio-Techne’s diagnostic technologies will enhance Merck’s healthcare research capabilities and improve disease detection solutions.
5. Academic & Clinical Research
Universities, hospitals, and research institutions will benefit from a broader range of integrated research products and workflow solutions.
Financial Benefits for Merck
According to Merck, the acquisition is expected to deliver significant long-term value.
The company expects:
- Around €140 million in annual cost synergies.
- Full realization of these synergies by the third year after closing.
- Immediate improvement in sales growth and EBITDA margin after the transaction.
- Earnings per share (EPS) accretion by the third year after completion.
What Will Bio-Techne Shareholders Receive?
If the acquisition is completed, every Bio-Techne shareholder will receive:
$73 in cash for each outstanding share.
The offer represents a 36% premium over Bio-Techne’s one-month volume-weighted average trading price, providing an attractive cash exit for investors.
Impact on Employees and Customers
Both companies have stated that business operations will continue normally until the acquisition is completed.
Customers can expect:
- No disruption in product availability
- Continued customer support
- Existing contracts to remain in place
Employees are also expected to continue their normal responsibilities while the companies prepare for integration after regulatory approval.
Will the Deal Receive Regulatory Approval?
Industry analysts believe the acquisition is strategically complementary because the two companies operate in different but highly related areas of the life sciences market.
As a result, many analysts do not expect major antitrust challenges.
However, the transaction still requires:
- Approval from Bio-Techne shareholders
- Regulatory approvals in multiple countries
- Satisfaction of customary closing conditions before completion.
What Does This Mean for Investors?
For Merck
- Stronger Life Science business
- Expanded biotechnology portfolio
- Greater exposure to high-growth healthcare markets
- Improved competitive position in advanced biological research
- Enhanced long-term growth opportunities
For Bio-Techne
- Immediate cash value for shareholders
- Access to Merck’s global commercial network
- Greater investment capacity for future innovation
- Broader worldwide customer reach
Challenges to Watch
Although the acquisition appears strategically attractive, investors should monitor several important factors:
- Regulatory approval timelines
- Integration of operations and corporate cultures
- Achievement of projected cost synergies
- Competition from other global life science companies
- Growth in biotechnology research spending
Successfully integrating both businesses will be essential for maximizing the long-term value of the transaction.
Outcome
The acquisition of Bio-Techne is more than just another corporate takeover—it is a strategic investment in the future of biotechnology.
The life sciences industry is rapidly shifting toward AI-powered research, multiomics, precision medicine, cell and gene therapy, and advanced biological analysis. Bio-Techne has built strong expertise in these fast-growing areas, while Merck contributes global manufacturing capabilities, a vast distribution network, and deep relationships with pharmaceutical customers.
Together, the combined company will be able to offer an end-to-end portfolio that supports researchers from basic scientific discovery to commercial biopharmaceutical production.
If the acquisition closes as planned, it is expected to become Merck KGaA’s largest Life Science acquisition in more than a decade and one of the most significant biotechnology deals of 2026, strengthening the company’s leadership in the global life sciences market.
Source: Sec
